Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 | Sarepta Therapeutics, Inc.
Sarepta's new PPMO drug will likely take out Exondy's 51 ...
![]()
- Forums
- ASX - By Stock
- Let’s go
Sarepta Therapeutics Announces Positive Data from Part B of...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
Add PER (ASX) to my watchlist
|
|||||
Last
8.1¢ |
Change
-0.002(2.41%) |
Mkt cap ! $73.92M |
Open | High | Low | Value | Volume |
8.1¢ | 8.2¢ | 8.0¢ | $39.27K | 485.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 365000 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 65393 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 365000 | 0.082 |
2 | 37265 | 0.081 |
3 | 88252 | 0.080 |
2 | 212658 | 0.078 |
1 | 108571 | 0.077 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 65393 | 4 |
0.085 | 90800 | 2 |
0.086 | 106100 | 2 |
0.087 | 65719 | 1 |
0.088 | 166793 | 7 |
Last trade - 14.51pm 11/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |